Boston Scientific (NYSE:BSX) announced today that it invested $1.5 billion in transcatheter aortic valve replacement (TAVR) developer MiRus.
Original Image Link
Source:www.massdevice.com
Original Image Link
Source:www.massdevice.com
Posted: 2026-05-18 04:29:00

















